Assignee
OGEDA SA
BE·19 granted patents·3 pending applications·15 citations·filing 2014–2023
Top patents by PatentIndex Score
22 records- 0185US9987274B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2016·Granted Jun 5, 2018·4 cites·19 claims
- 0284US11478472B2NK-3 receptor antagonists for therapeutic treatment of leptin-related diseaseOGEDA SA·Filed 2020·Granted Oct 25, 2022·1 cites·8 claims
- 0384US10787458B2Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazinesOGEDA SA·Filed 2019·Granted Sep 29, 2020·2 cites·14 claims
- 0482US10836768B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2018·Granted Nov 17, 2020·1 cites·12 claims
- 0582US2024199618A1NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERSOGEDA SA·Filed 2023·Application pending·0 cites
- 0681US10183948B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2017·Granted Jan 22, 2019·1 cites·13 claims
- 0780US10624890B2NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatOGEDA SA·Filed 2016·Granted Apr 21, 2020·2 cites·10 claims
- 0879US9969745B2N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersOGEDA SA·Filed 2017·Granted May 15, 2018·2 cites·11 claims
- 0978US12458641B2NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatOGEDA SA·Filed 2022·Granted Nov 4, 2025·0 cites·4 claims
- 1075US11078203B2Deuterated fezolinetantOGEDA SA·Filed 2018·Granted Aug 3, 2021·1 cites·9 claims
- 1174US10683295B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2018·Granted Jun 16, 2020·1 cites·5 claims
- 1273US11731974B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2020·Granted Aug 22, 2023·0 cites·8 claims
- 1367US10941151B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2020·Granted Mar 9, 2021·0 cites·4 claims
- 1464US2020125564A1Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disordersOGEDA SA·Filed 2019·Application pending·0 cites
- 1562US10358416B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsOGEDA SA·Filed 2018·Granted Jul 23, 2019·0 cites·2 claims
- 1661US9926325B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2014·Granted Mar 27, 2018·0 cites·4 claims
- 1759US10544150B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2018·Granted Jan 28, 2020·0 cites·12 claims
- 1859US10017468B2Substituted pyrrolidines as G-protein coupled receptor 43 agonistsOGEDA SA·Filed 2017·Granted Jul 10, 2018·0 cites·3 claims
- 1954US12162849B2Synthesis of 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or of the methyl-d3 deuterated form thereofOGEDA SA·Filed 2019·Granted Dec 10, 2024·0 cites·17 claims
- 2052US10214533B2N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersOGEDA SA·Filed 2018·Granted Feb 26, 2019·0 cites·9 claims
- 2150US2017298070A1Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazinesOGEDA SA·Filed 2015·Application pending·0 cites
- 2236US10065960B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2015·Granted Sep 4, 2018·0 cites·12 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →